Latest Institute for Quality and Efficiency Stories
In the commenting procedure on early benefit assessment pursuant to the German Act on the Reform of the Market for Medicinal Products (AMNOG), under certain circumstances drug manufacturers may submit to the Federal Joint Committee (G-BA) additional documents for dossiers.
Insufficient trials -- no conclusions possible on diabetes-related diseases.
Long-term research is lacking â€“ potential harm remains unclear â€“ valid studies are urgently needed for growing and developing children and adolescents.
IQWiG presents its final report on pediatric oncological care -- still insufficient research into quality of life, pain and long-term consequences.
However, bupropion XL and mirtazapine can benefit people suffering from depression.
Manufacturers who conceal data are harming patients and hindering the work of IQWiG and the G-BA.
There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine.
The risk of cancer possibly increases if patients with diabetes use the long-acting insulin analogue glargine instead of human insulin.
- A young chicken: also used as a pet name for children.